AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

Sources

Coverage

Limited spectrum

Sentiment

0.00

◀ Left 100%Centre 0%Right 0% ▶

How we rate bias →

This story is currently only covered by one source from a single part of the political spectrum. NewsDeck will update this page automatically if other outlets pick up the story.

shopping_bagPolitical Documentaries

Documentary box sets covering elections, Westminster, and modern British political history.

Browse documentaries on Amazonarrow_forward

NewsDeck Poll

Do you think this story is being covered fairly across the political spectrum?

Loading…

Left

(1)

Guardian Business

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has been a triumph, starting with the against-the-odds victory over Pfizer’s charmless accountants in 2014. The $39bn (£29bn…